ReviewClinical microbiology reviews2014
Disease manifestations and pathogenic mechanisms of Group A Streptococcus.
Review in Clinical microbiology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 520 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
520 citing papers in PubMed, 3 syntheses or guidelines pooled it, 904 citations in OpenAlex.
- Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Presence of Group A streptococcus frequently assayed virulence genes in invasive disease: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Gut bacterial profiles in Parkinson's disease: A systematic review.CNS neuroscience & therapeutics · 2023Pooled it
- Tracing the recent evolution of Group AEmerging microbes & infections · 2026Review
- Molecular mechanism of complement interference by Streptococcus pyogenes nuclease A.Communications biology · 2026Article
- Genomic analysis and clinical characteristics of a seasonal upsurge of Streptococcus pyogenes emm12.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Clinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Review
- Article
- Suspected Group A Streptococcal Urethritis Following Orogenital Exposure in a Young Adult Male.Cureus · 2026Article
- Invasive group A streptococcal infections requiring paediatric intensive care in children and adolescents: a nationwide retrospective cohort study in Austria.European journal of pediatrics · 2026Observational
- A Rare Case of Acute Rheumatic Fever Diagnosed After Recent Travel Abroad.Infectious disease reports · 2026Article
- Comparative Analysis of Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Article
- Detection of asymptomatic group AMicrobiology spectrum · 2026Observational
- Evaluation of a chromogenic medium, CHROMagar StrepA, for the detection ofMicrobiology spectrum · 2026Article
- Dynamic tethering of M protein drives pathological inflammation during group A Streptococcus infections.PLoS pathogens · 2026Article
- From vesicles to ventricles: pediatric group a streptococcal meningitis post-varicella infection - a case report.BMC infectious diseases · 2026Article
- Molecular characterization of covRS mutations in M1FEBS open bio · 2026Article
- Prophages in Skin Pathogens: From Virulence to Therapy.Pathogens (Basel, Switzerland) · 2026Review
- Article
- Panophthalmitis and necrotizing fasciitis following glaucoma drainage device surgery: A case report.American journal of ophthalmology case reports · 2026Article
460 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Streptococcus pyogenes, also known as group A Streptococcus (GAS), causes mild human infections such as pharyngitis and impetigo and serious infections such as necrotizing fasciitis and streptococcal toxic shock syndrome. Furthermore, repeated GAS infections may trigger autoimmune diseases, including acute poststreptococcal glomerulonephritis, acute rheumatic fever, and rheumatic heart disease. Combined, these diseases account for over half a million deaths per year globally. Genomic and molecular analyses have now characterized a large number of GAS virulence determinants, many of which exhibit overlap and redundancy in the processes of adhesion and colonization, innate immune resistance, and the capacity to facilitate tissue barrier degradation and spread within the human host. This improved understanding of the contribution of individual virulence determinants to the disease process has led to the formulation of models of GAS disease progression, which may lead to better treatment and intervention strategies. While GAS remains sensitive to all penicillins and cephalosporins, rising resistance to other antibiotics used in disease treatment is an increasing worldwide concern. Several GAS vaccine formulations that elicit protective immunity in animal models have shown promise in nonhuman primate and early-stage human trials. The development of a safe and efficacious commercial human vaccine for the prophylaxis of GAS disease remains a high priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.